biostudies-literatureUnknown27(26)Viprey VFMedical Research CouncilBackgroundThere is a paucity of data on community-based <i>Clostridioides difficile</i> infection (CDI) and how these compare with inpatient CDI.AimTo compare data on the populations with CDI in hospitals vs the community across 12 European countries.MethodsFor this point-prevalence study (July-November 2018), testing sites sent residual diagnostic material on sampling days to a coordinating laboratory for CDI testing and PCR ribotyping (n = 3,163). Information on whether CDI testing was requested at the original site was used to identify undiagnosed CDI. We used medical records to identify differences between healthcare settings in patient demographics and risk factors for detection of <i>C. difficile</i> with or without free toxin.ResultsThe CDI positivity rate was 4.4% (country range: 0Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletinhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC9248264biostudies-literatureA point-prevalence study on community and inpatient &lt;i&gt;Clostridioides difficile&lt;/i&gt; infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018.PMC9248264MR/W005530/1Cleuziat PViprey VFRupnik MSpittal WPetrosillo NCOMBACTE-CDI National CoordinatorsCOMBACTE-CDI consortiumMatussek AAllantaz FRamirez ERDavis GLBanz AEwin DPetinaki EBenson ADVernon JJWilcox MHKuijper EMacovei ISimon ADavies KAFitzpatrick FBarbut FPituch HMembers of the COMBACTE-CDI National coordinatorsNovakova EfalseA point-prevalence study on community and inpatient &lt;i&gt;Clostridioides difficile&lt;/i&gt; infections (CDI): results from Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI), July to November 2018.BackgroundThere is a paucity of data on community-based <i>Clostridioides difficile</i> infection (CDI) and how these compare with inpatient CDI.AimTo compare data on the populations with CDI in hospitals vs the community across 12 European countries.MethodsFor this point-prevalence study (July-November 2018), testing sites sent residual diagnostic material on sampling days to a coordinating laboratory for CDI testing and PCR ribotyping (n = 3,163). Information on whether CDI testing was requested at the original site was used to identify undiagnosed CDI. We used medical records to identify differences between healthcare settings in patient demographics and risk factors for detection of <i>C. difficile</i> with or without free toxin.ResultsThe CDI positivity rate was 4.4% (country range: 02022-01-01T00:00:00Z2022 Jun2026-05-27T19:15:53.061Z2022-07-21T11:04:37.598ZS-EPMC92482643577542610.2807/1560-7917.ES.2022.27.26.2100704